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Abstract
Background Streptococcus pneumoniae is a pathogen
causing acute respiratory infections, as well as meningitis
and bacteremia. The province of Alberta, Canada, began
vaccinating infants against seven S. pneumoniae serotypes
in 2002 using Prevnar 7 (PCV7). However, a 13-valent
conjugate vaccine (PCV13) was introduced in 2010 to
address changes in the distribution of serotypes causing
disease. PCV13 targets 13 serotypes including six addi-
tional serotypes to the previously adopted PCV7.
Objective In this study, we estimate the impact of the
new PCV13 immunization program on the burden of dis-
ease and related healthcare costs in Alberta.
Methods Serotype-specific passive surveillance invasive
pneumococcal disease (IPD) data were drawn from the
Alberta Public Health Laboratory. These data were used to
estimate average annual IPD incidence of the six additional
serotypes included in PCV13 during the PCV7 era
(2000–2009), and after the introduction of PCV13
(2011–2015). The difference in estimated cases pre-/post-
PCV13 was used to estimate associated changes in direct
health service costs.
Results Following the replacement of PCV7 with
PCV13 in 2010, the number of cases of IPD caused by the
additional serotypes contained in PCV13 has declined
significantly across all ages. The expected number of IPD
cases prevented annually is an estimated 1.6 per 100,000.
Direct health service costs are expected to be averted as a
result of the implementation of PCV13 universal vacci-
nation in Alberta. Indirect benefits are experienced by
ages[20 years as IPD incidence significantly declines
following the PCV13 infant immunization in Alberta.
Conclusion The impact on direct healthcare costs of
replacing PCV7 with PCV13 in Alberta’s public immu-
nization program are estimated to be CAN$3.5 million as
of 2015.
Key Points
The distribution of Streptococcus pneumoniae
serotypes causing invasive pneumococcal disease
changed over time, following the introduction of
Prevnar 7. As a result, value has been added by
replacing Prevnar 7 with Prevnar 13 in Alberta’s
childhood immunization program.
Public immunization programs should be evaluated
to inform policy makers of resulting changes in
disease incidence and associated healthcare costs.
1 Introduction
Streptococcus pneumoniae is a pathogen causing acute
respiratory infections, as well as meningitis and bac-
teremia. There is a high burden of disease attributable to S.
pneumoniae in the form of invasive pneumococcal disease
(IPD), and non-invasive pneumococcal disease (NIPD).
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Invasive disease can result in a range of clinical presenta-
tions, including invasive pneumonia, meningitis, or bac-
teremia; sequelae can include death. NIPD is less severe
and generally presents as either acute otitis media (in
children only) (AOM), or non-bacteremic pneumonia.
Research has shown that conjugate polysaccharide
vaccines, administered to children, have been both clini-
cally effective [1] and cost effective at reducing the cases
of pneumococcal disease via direct and indirect protection
[2, 3]. Consequently, in 2002, a seven-valent conjugate
vaccine, Prevnar 7 (PCV7), was introduced to protect
against serotypes 4, 6B, 9V, 14, 18C, 19F and 23F, in
Alberta, Canada. However, within a few years of the
introduction of PCV7, changes in the distribution of S.
pneumoniae serotypes were observed [4, 5]. This phe-
nomenon, termed serotype replacement, reflects an emer-
gence or increase in the frequency of cases caused by non-
vaccine serotypes following the introduction of PCV7. For
example, serotypes 5 and 19A showed the most dramatic
increases following PCV7 in Alberta, increasing 96 %
from 0.1 per 2000 to 2.25 per 100,000 in 2008 [6].
A 13-valent conjugate vaccine (PCV13) was introduced
in Alberta, Canada in 2010 to address observed changes in
serotype distribution. PCV13 targets 13 serotypes includ-
ing six additional serotypes (1, 3, 5, 6A, 7F, 19A) to the
previously adopted PCV7. The purpose of this study is to
estimate the added value of adopting PCV13 relative to
PCV7 as a result of reduced health service resource use
between 2010 when PCV13 was introduced and the present
year, 2015.
The objective of this study is to estimate the added value
of introducing PCV13 in the Alberta childhood immu-
nization schedule over and above that gained as a result of
PCV7 between the year of introduction (2010) and the
current year (2015).The impact on health service resource
use and costs will be estimated using real-world observa-
tional data. Given that 7 of the 13 serotypes were targeted
by the previously administered PCV7, we estimated health
service use and associated costs for the six new serotypes
covered by PCV13 (1, 3, 5, 6A, 7F, 19A) between 2000
and 2015 based upon the observed and forecast change in
vaccine serotypes following the introduction of PCV7.
2 Methods
A prospective population-based surveillance program has
tracked the incidence of IPD by serotype in Alberta,
Canada since 2000 [7]. Using this serotype-specific data,
observed (2000–2013) and predicted (2014–2015) cases of
IPD in the province were estimated, as well as the reduc-
tion in resulting health service costs.
2.1 IPD Surveillance Data and Forecast Data
The Canadian national case definition for IPD is isolation
of a positive culture of S. pneumoniae from normally
sterile body fluid, primarily blood or cerebrospinal fluid
[8]. IPD is a notifiable health condition to Provincial Public
Health Authorities in Alberta. This leads to all pneumo-
coccal isolates from cases of IPD being forwarded to the
Provincial Public Health Laboratory in Edmonton, Alberta
for serotype analysis [7]. Details regarding the program are
published elsewhere [7]. Data consisting of reported IPD
cases by age, between 2000 and 2013, were obtained from
the Provincial Public Health Laboratory and used in the
present analysis. These data allow for identification of the
seven serotypes targeted by PCV7, as well as the additional
six serotypes included in PCV13, which will be referred to
as ‘incremental serotypes’ for the remainder of this paper.
To examine the value added of PCV13 over and above
PCV7, age-specific incidence and fatality rates of IPD in
Alberta were estimated based on ascertained cases subdi-
vided into seven categories (\2, 2–4, 5–9, 10–19, 20–64,
65? years), using population data drawn from Statistics
Canada, and [10].
Age-specific annual incidence rates of the incremental
serotypes were estimated post-implementation based upon
observed cases between 2010 and 2013. Due to the
unavailability of data for 2014 and 2015, incidence rates
for these additional six serotypes were forecasted based
upon the trends observed in PCV7.1
Forecasts were made assuming the impact of PCV13 on
burden of disease will follow the same trend as PCV7. As
such, age-specific year-over-year percentage changes in
PCV7 incidence between 2003 and 2007 were applied to
incidence rates for corresponding years of vaccine intro-
duction for the six additional serotypes included in PCV13
(year of vaccine introductions were matched (2002 and
2010), and each subsequent year was matched for the fol-
lowing 5 years).2 The first observation used to predict
incremental serotype incidence was the average age-
specific incidence between 2009 and 2010. These fore-
casted incidence rates were validated by comparing pre-
dicted IPD cases between 2011 and 2013 to observed IPD
cases in Alberta during this same time period.
1 According to Hyndman and Athanasopoulus, it is best to use per-
capita data rather than totals for data affected by population change.
As a result, incidence rates were forecast instead of total annual cases
[9].
2 A number of functional forms were examined when analyzing the
trend in PCV7 IPD incidence. However, each functional form and
associated data transformation resulted in very similar predicted
incremental serotype incidence and resulting costs. As a result, the
simplest method assuming linear year-over-year declines in incidence
was applied.
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The IPD incidence rates were reported by presenting
diagnosis, and calculated by applying the distributions of
pneumococcal disease states previously calculated by
Morrow et al. [11] to observed IPD annual age-specific
incidence rates in Alberta (Table 1). Case fatality rates
were drawn from this same study [11] and applied to
Alberta IPD age-specific observed incidence rates.
2.2 Costing Model
Using actual (2011–2013) IPD surveillance data and pre-
dicted IPD incidence (2014–2015), an economic model
was developed to compare the direct medical costs averted
resulting from replacing PCV7 with PCV13. The changes
in incidence of S. pneumoniae disease caused by the six
additional (incremental) serotypes and associated health
service resource use were estimated.
We adopted a direct payer perspective, including costs
related to direct medical services associated with IPD for
incremental serotypes. Changes in costs resulting from
direct and indirect vaccine protection were taken into
account from 2011 to 2015. There is no cost difference
between PCV7 and PCV13, and therefore is not included in
this analysis. The changes in frequency of IPD and asso-
ciated cost impact following the introduction of Prevnar 13
are estimated using Microsoft Excel 2012.
2.2.1 Method for Calculation of Direct Medical Costs
Averted as a Result of PCV13
The number of cases averted were estimated as the dif-
ference between the average incremental serotype inci-
dence during the PCV7 era (pre-PCV13 between 2000 and
2009), and following the replacement of PCV7 with
PCV13 (post-PCV13 between 2011and 2015). Because of
differences in medical service costs across disease state and
age, cases averted were calculated according to age-
specific rates of IPD caused by incremental serotypes and
presenting diagnosis, as well as IPD-related mortality.
Direct health service costs were then applied to age-
specific numbers of IPD cases by presenting diagnosis
(pneumonia, bacteremia, meningitis), and number of deaths
from incremental serotypes.3 The estimated cost associated
with a case fatality is CAN$34,789, taken from a study on
end-of-life care for patients suffering from infection [12].
All costs were adjusted to reflect 2014 Canadian dollars
using the Canadian Consumer Price Index, and 2015 cost
estimates are discounted using a 3 % discount rate.
As with a previous publication [6], the costs averted
were estimated by first calculating the difference between
the average annual incidence of incremental serotypes
while PCV7 was being administered (pre-PCV13, between
2000 and 2009), and following the replacement of PCV7
with PCV13 (post-PCV13, between 2011 and 2015), by
presenting diagnosis. We excluded the first year of the
vaccination program (2010) to allow for a wash-out period.
Second, the difference in estimated annual incidence was
then multiplied by the number of Albertan’s in each age
category to estimate the average number of cases pre- and
post-PCV13 implementation. Cases averted were calcu-
lated as the difference between the estimated average
Table 1 Epidemiology and
direct health service costs (2014
CAN$) [11]
Age groups (years)
\2 2–4 5–9 10–19 20–64 65?
Distribution of invasive pneumococcal disease (IPD) by presenting diagnosis (%)
Hospitalized pneumonia 74.00 74.00 88.20 62.40 66.90 81.50
Hospitalized bacteremia 14.30 14.30 6.70 24.80 26.30 15.00
Non-hospitalized bacteremia 8.90 8.90 4.10 9.60 5.10 2.90
Meningitis 2.50 2.50 1.00 3.20 1.70 0.60
Mortality (%)
Hospitalized pneumonia 1 1 1 2 2 2
Bacteremia 2 2 2 2 15 31
Meningitis 7 7 7 7 28 28
Direct health service costs (CAN$)
Meningitis 38,070 38,070 35,857 35,857 15,406 12,289
Hospitalized bacteremia 7124 7124 5576 5576 12,714 12,271
Non-hospitalized bacteremia 155 155 155 155 155 155
Hospitalized pneumonia 2920 2920 4690 7789 8289 8731
3 Direct health service costs include the cost of hospitalization and
outpatient costs. Costs of health care vary across age and disease
presentations. The direct costs accounted for in this analysis include
health service costs resulting from hospitalization for IPD outpatient
care, as well as any subsequent hospitalizations. These costs of
treatment and sequelae for survivors of IPD are taken from Morrow
et al. (Table 1) [11].
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number of incremental serotype cases pre- and post-
PCV13. July 2013 population data, which represent the
midpoint between 2011 and 2015, were used to generate an
estimate of the total cases pre- and post-PCV13 imple-
mentation. Third, to calculate the annual total PCV13 costs
averted, we multiplied the estimated total cases averted in
Alberta per year by the average cost per case. The average
cost per case was previously estimated by Morrow et al.
and was used in the present study (Table 1) [11].
2.3 Direct and Indirect Vaccine Protection
In 2010, at the time of universal PCV13 vaccination in
Alberta, only children reaching 2 months of age were tar-
geted. Children older than 2 months were not offered the
vaccine unless they belonged to a high-risk group [13]. In
this study, the measure of direct vaccine protection against
IPD is the difference between annual incidence before and
after vaccine introduction by presenting diagnosis for
children vaccinated.
Indirect protection is assumed to apply to the non-
vaccinated population as a result of the decreased circu-
lation of the disease. This is evidenced by a decrease in
annual incidence of IPD following the vaccine introduc-
tion [4, 5, 14]. Indirect protection was estimated as the
difference between the annual incidence of unvaccinated
people across the 5-year post-vaccination program (ages
10 years and older), by presenting diagnosis, pre- and
post-PCV13. The youngest age considered for evidence of
indirect protection was 10 years, since by 2015 children




The estimated health resource use and associated costs are
based upon the underlying annual incidence rates of
S. pneumoniae caused by serotypes contained in PCV13.
The annual incidence per 100,000 caused by PCV7 ser-
otypes in Alberta decreased from a high of roughly 7.5 in
2000 to approximately 0.78 in 2010 (Fig. 2). The annual
incidence of incremental serotypes, on the other hand,
increased from 1.8 per 100,000 in 2000 to 3.4 in the year of
vaccine introduction (2010). There was an outbreak of
serotypes 5 and 19A in Alberta in 2006 and 2007.
The total incidence of incremental vaccine serotypes
from 2011 to 2015 will have declined by an estimated 1.6
cases by 2015, assuming PCV13 follows a similar trend to
PCV7 following vaccine introduction (Fig. 1). Estimated
age-specific IPD incidence can be found in Table 2.
The health impacts of serotypes 5 and 19A are expected
to be significantly reduced by 2015 as a result of PCV13
(Fig. 2).
Children aged\4 years, and adults aged 20 years and
older had the highest incidence of IPD caused by incre-
mental serotypes before vaccine introduction (Table 2).4
Direct protection is expected to result in a nearly complete
decline in incidence for children younger than 4 years.
Those aged 10–19 years had low incidence prior to vaccine
introduction, and therefore are not expected to decline as
dramatically as other ages. Adults are expected to see
significant declines from 2.8 cases per 100,000 in 2010 to
1.4 cases per 100,000 5 years after the vaccine is intro-
duced. Overall, we predict that between 2011 and 2015
PCV13 serotypes will decrease by 69 % from 3.43 per
100,000 in 2010 to 1.6 per 100,000 in 2015. The annual
number of IPD cases averted per 100,000, caused by
incremental serotypes, ranges from 0.3 in ages 10–19 years
to 6.6 in ages\2 years.
3.2 Direct Service Cost Impacts
The direct health service costs averted by the health min-
istry as a result of the observed declines in incremental
serotypes are expected to amount to over CAN$699,000
per year in Alberta, or CAN$3.5 million over the 5 years
after PCV13 immunization program implementation
(Table 3). The greatest savings in health service costs are
found in the adult age categories. Specifically, on net, those
aged 20–64 years averted costs of CAN$546,000 annually,
or an estimated CAN$2.7 million over the 5 years post-
vaccination. The next most significant savings were the
elderly with indirect protection resulting in CAN$101,000
saved annually, or CAN$502,000 over the 5 years post-
vaccination. Direct protection resulted in CAN$51,000
saved annually for ages B19 years, amounting to
CAN$255,000 over the 5 years post-vaccination.
The costs attributed to serotype 5 and 19A account for
68 % of the costs averted as a result of the vaccine
(CAN$2.4 million) (Table 4). The benefits are mostly
accrued to those aged 20–64 years (CAN$2.3 million),
who tend to experience the greatest burden of disease
caused by these two serotypes.
4 Discussion
In this study, we analyzed the expected cost impact to the
health system from replacing PCV7 with PCV13 in
Alberta’s childhood vaccination strategy. As such, we
4 Detailed incidence disaggregated by disease state available upon
request.
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estimated the total value added as a result of exchanging
PCV7 for PCV13 to be CAN$3.5 million as of this year
(2015). This estimate of costs averted is based upon
observed declines in incremental serotype incidence (be-
tween 2011 and 2013), as well as predicted declines in
2014 and 2015.
Between 2011 and 2015 we estimate PCV13 incre-
mental serotypes to have decreased by 69 % from 3.6 per
100,000 in 2009–2010 to 1.1 per 100,000 in 2015. The
number of IPD cases averted is an estimated 1.6 per
100,000, or 65 cases in Alberta per year (Table 2).
Ages\2 years are expected to experience upwards of 6.7
IPD cases averted per 100,000, while ages 20 years and
older are predicted to experience between 2.0 and 2.1 IPD
cases averted per 100,000.
While explicit assumptions regarding efficacy of PCV13
are not made in this analysis, it is expected that PCV13 will
be as effective as PCV7; it has been shown that immuno-
genic response to PCV13 vaccine is comparable to PCV7
[15]. As a result, we assume that the decline in the
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
PCV7 Incidence (4, 6B, 9V, 14, 18C, 19F,
23F) 7.5 7.6 6.9 6.1 4.4 3.4 2.5 2.2 1.8 1.1 0.8 1.3 1.0 0.5
PCV13 Incidence 9.3 9.9 9.5 8.8 6.5 6.5 9.8 10.9 5.6 4.9 4.2 4.7 3.7 2.0
Incremental serotype incidence 1.8 2.4 2.6 2.7 2.1 3.0 7.2 8.8 3.9 3.8 3.4 3.4 2.7 1.4
























Prevnar 7, a seven-valent
conjugate vaccine
Table 2 Incremental serotype (1, 3, 5, 6A, 7F, 19A) invasive pneumococcal disease (IPD) incidence per 100,000
Year Age groups (years)
\2 2–4 5–9 10–19 20–64 65? Total
PCV7
2000 0.0 0.9 0.9 0.2 2.1 4.1 1.8
2001 9.3 6.9 2.4 1.3 1.5 6.1 2.4
2002 9.3 3.4 0.5 0.9 2.1 7.5 2.6
2003 10.4 4.3 1.0 1.1 2.6 4.9 2.7
2004 10.0 2.6 0.0 0.0 1.5 7.8 2.1
2005 8.4 1.7 1.0 1.1 3.0 6.4 3.0
2006 11.6 5.6 1.0 1.7 8.9 7.6 7.2
2007 16.4 7.0 0.5 1.7 10.9 8.3 8.8
2008 13.4 3.0 0.5 0.2 4.1 7.0 3.9
2009 16.9 3.7 3.3 0.4 3.1 8.9 3.8
PCV13
2010 12.8 5.6 2.3 0.0 2.8 8.9 3.4
2011 5.7 6.7 2.4 0.3 3.2 7.4 3.0
2012 2.2 4.2 2.8 0.3 2.4 6.9 2.2
2013 1.9 2.5 0.8 0.0 2.0 6.3 1.7
2014a 0.8 0.9 3.2 0.1 1.8 2.7 1.2
2015a 0.4 0.6 0.8 0.2 1.4 3.7 1.1
Annual average cases averted (2000–2009 vs 2011–2015) 6.6 1.2 -0.2 0.3 2.0 2.1 1.6
Annual average lives saved (2000–2009 vs 2011–2015) 0.08 0.01 0.00 0.01 0.11 0.13 0.09
Percentage change (2009–2010 vs 2015) -97 % -86 % -71 % -23 % -51 % -58 % -69 %
a Forecasted results
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incidence of incremental serotypes will follow a similar
trend to the seven serotypes targeted by PCV7. These
declines are in part due to high efficacy, in addition to
strong indirect protection (herd effects). Declines in inci-
dence following PCV7 were experienced not only by
infants immunized (direct protection), but also by popula-
tions not immunized (indirect protection). Direct protection
as a result of PCV13 is anticipated to result in CAN$19,000
saved annually for ages\10 years, amounting to
CAN$100,000 over the 5 years post-vaccination. Those
aged 20–64 years as well as those 65? years are found to
have benefited from the PCV13 childhood immunization
program through indirect protection in the same way that
was experienced as a result of PCV7. Specifically, cases
averted in ages 20–64 years are expected to decline from
2.8 in 2010 to 1.4 in 2015, amounting to an estimated
CAN$2.7 million averted over the 5 years post-vaccina-
tion. Similarly, it is estimated that incidence rates for those
aged 65 years and older will decline from 8.9 per 100,000
in 2010 to 3.7 per 100,000 in 2015, resulting in
CAN$502,000 in direct medical costs averted by 2015.
Serotypes 5 and 19A were found to significantly
increase following PCV7, from 0.1 per 100,000 in 2000 to
1.7 per 100,000 in 2009. An outbreak in 2006 and 2007
resulted in rates as high as 5.9 per 100,000 [7]. This out-
break mostly affected children aged\2 years, with inci-
dence of 11 per 100,000, as well as adults aged
20–64 years with 9.4 cases per 100,000. The inclusion of
these serotypes in PCV13 is predicted to result in signifi-
cant declines in incidence, and resulting costs. Of the costs
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014f 2015f
PCV7 Incidence (4, 6B, 9V, 14,
18C, 19F, 23F) 7.5 7.6 6.9 6.1 4.4 3.4 2.5 2.2 1.8 1.1 0.8 1.3 1.0 0.5
Serotypes 5 and 19A Incidence 0.1 0.3 0.1 0.2 0.4 1.5 5.9 7.2 2.3 1.7 1.4 1.2 1.1 0.4
Forecast Incidence Serotype 5























Fig. 2 Incidence of IPD caused
by serotypes 5 and 19A.
f Forecasted, IPD invasive
pneumococcal disease, PCV7
Prevnar 7, a seven-valent
conjugate vaccine
Table 3 Health service costs averted ($CAN) (2000–2009 vs 2011–2015) for incremental serotypes (1, 3, 5, 6A, 7F, 19A)
Age groups (years)
\2 2–4 5–9 10–19 20–64 65? Total
Annual average cost pre-PCV13 vaccine (2000–2009) $50,714 $27,868 $14,014 $31,763 $1,080,470 $324,038 $1,528,866
Annual average cost post-PCV13 (2011–2015) $18,966 $19,042 $15,796 $19,192 $534,187 $223,052 $830,234
Annual difference in average cost pre/post-PCV13 $31,748 $8,826 ($1782) $12,571 $546,283 $100,986 $698,632
Total cumulative cost averted post-PCV13 $157,814 $43,872 ($8859) $62,488 $2,715,505 $501,990 $3,472,810
Values in parentheses represent negative values
Table 4 Predicted health service costs averted (CAN$) (2000–2009 vs 2011–2015) for serotypes 5, 19A
Age groups (years)
\2 2–4 5–9 10–19 20–64 65? Total
Annual average cost pre-PCV13 vaccine (2000-2009) $26,974 $12,818 $4849 $13,290 $640,383 $79,888 $778,201
Annual average cost post-PCV13 (2011–2015) $9242 $11,049 $6795 $4729 $180,482 $84,593 $296,891
Annual difference in average cost pre/post-PCV13 $17,732 $1769 ($1946) $8561 $459,901 ($4705) $481,311
Total cumulative cost averted post-PCV13 (5 years) $88,142 $8793 ($9672) $42,554 $2,286,109 ($23,390) $2,392,535
Values in parentheses represent negative values
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averted due to PCV13, an estimated CAN$2.4 million is
attributed to serotypes 5 and 19A. Those ages that expe-
rienced the most significant burden of illness from these
serotypes are predicted to experience the most significant
declines in incidence and related direct health service costs.
In particular, incidence in ages 20–64 years is predicted to
decline from 0.9 in 2010 to 0.53 in 2015, and result in costs
averted of more than CAN$2.3 million over the 5 years.
Ages 65 years and above are not predicted to experience
the same cost reductions despite predicted declines from
4.3 to 1.1 per 100,000 between 2010 and 2015. This is due
to very similar average incidence over the two time peri-
ods, as there was\1 case per 100,000 each of the years
prior to 2006. The same is true for ages 5–9 years as a
spike in cases of 19A in 2009 and 2010 resulted in a higher
baseline incidence rate used for forecasting. Meanwhile,
there was\1 case per 100,000 for each of the years
between 2002 and 2008.
Streptococcus pneumoniae comprises more than 90
serotypes, as characterized by select features exhibited
within the bacteria’s cell wall. These bacteria are known to
be very pliant and can easily modify their external struc-
ture, and therefore change serotype. Selection pressures
such as the presence of antibiotics (antibiotic resistance)
and vaccine coverage are believed to cause a shift in
pneumococcal serotypes [16]. However, little is known
about ‘normal’ colonization (i.e., without any selection
pressures), or about serotype replacement as a result of the
conjugate vaccine in the absence of antibiotics [16]. The
microbiology regarding S. pneumoniae and how PCV7
may have led to the replacement (increased frequency) of
serotypes is not well understood. The current body of
evidence concerning the association between PCV7 and
serotype replacement has been generated through obser-
vational studies; numerous surveillance programs interna-
tionally have reported serotype replacement following
PCV7 [17]. However, these increases in IPD cases were
found to be less than the reductions in IPD due to PCV7
[17]. In general, it was found that changes in the distri-
bution of serotypes causing disease were evident within
3 years [17, 18]. We find slight increases in IPD caused by
non-PCV13 serotypes; however, the increase is roughly
half of what was observed 3 years after the introduction of
PCV7. In a previous study, we estimated that post-PCV7
serotype replacement would result in a 30 % reduction in
costs averted as a result of the vaccine [6]. Given that
serotype replacement post-PCV13 is expected to be less
than post-PCV7, our cost estimates may overstate the costs
averted by at most CAN$1million, resulting in a minimum
total health service cost averted of CAN$2.5 million.
Results from this study should be considered with regard
for study limitations. First, future serotype replacement
was excluded from the present analysis because it is
uncertain which serotypes will increase as a result of
PCV13. The science regarding the causality and pre-
dictability of the change in distribution of serotypes is not
well developed, and therefore excluded. The costs esti-
mated in this study may overestimate the actual costs
averted if serotype replacement does occur in the future.
Second, there is some uncertainty concerning the estimated
changes in incidence for ages 5–9 years and 10–19 years
because of small incidence rates and associated variation
year over year. For example, for ages 5–9 years, an
increase from two cases to four cases in the 2 years pre-
ceding the new PCV13 immunization program resulted in
the average incidence (and related cost) post-vaccination
being larger than pre-vaccination. The results for these age
groups should be interpreted with caution. Third, our 2013
observed incidence data is incomplete, as we have only
obtained data until the end of November. As a result, the
actual data for 2013 understates the true incidence for this
year. However, using forecast 2013 incidence rates in this
analysis changed the estimated costs averted by less than
CAN$65,000 annually, suggesting that potential missed
cases from December 2013 would have little impact on the
results. Fourth, disease incidence may be affected by
multiple factors, including not only the immunization
program, but also demographic changes, or trends in the
variety and virulence of the infectious disease itself. Lastly,
NIPD has not been included in this study due to the lack of
incidence data on cases of NIPD.
5 Conclusion
The direct health costs averted from replacing PCV7 with
PCV13 in Alberta are estimated to amount to CAN$3.5
million between 2011 and 2015 as a result of the additional
six serotypes (1, 3, 5, 6A, 7F, 19A) included in PCV13.
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